CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

Activating KRAS mutations are found in approximately 20% of human cancers but no RAS-directed therapies are currently available. Here we describe a novel, robust, KRAS synthetic lethal interaction with the cyclin dependent kinase, CDK1. This was discovered using parallel siRNA screens in KRAS mutant...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa-Cabral, Sara, Brough, Rachel, Konde, Asha, Aarts, Marieke, Campbell, James, Marinari, Eliana, Riffell, Jenna, Bardelli, Alberto, Torrance, Christopher, Lord, Christopher J., Ashworth, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755568/
https://www.ncbi.nlm.nih.gov/pubmed/26881434
http://dx.doi.org/10.1371/journal.pone.0149099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755568/
https://www.ncbi.nlm.nih.gov/pubmed/26881434
http://dx.doi.org/10.1371/journal.pone.0149099

Ejemplares similares